Finanical Reports

Explore the landscape of Finanical Reports in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Finanical Reports to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Bayer's Sunharbo (Asundexian) Secures NMPA Approval in China – World's First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA
CompanyDrug

Bayer’s Sunharbo (Asundexian) Secures NMPA Approval in China – World’s First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA

Bayer AG (ETR: BAYN) announced that China's National Medical Products Administration (NMPA) has approved Sunharbo (asundexian tablets), the world's first (first‑in‑class) activated Factor XI (FXIa) inhibitor, for reducing the risk…

Hansoh Pharma Pledges RMB 100 Million Donation to the China Foundation for Science and Technology Development – Strategic Partnership to Fund Scientific Innovation, Talent Development and Health Communication

Hansoh Pharma Pledges RMB 100 Million Donation to the China Foundation for Science and Technology Development – Strategic Partnership to Fund Scientific Innovation, Talent Development and Health Communication

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Company

Bayer AG Reports Q2/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals

Company

Zai Lab Ltd Reports Q2 2023 Financials with 53% YOY Product Revenue Growth

Company

Gilead Sciences Inc. Reports 5% YOY Revenue Increase in Q2 2023 Financials

CompanyLegal / IP

Amgen Inc. Reports 7% YOY Revenue Increase in Q2 2023 Financials

Company

BeiGene’s Q2 2023 Financial Report Highlights 81.8% YOY Product Revenue Growth

Company

Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials

Company

Pfizer Inc. Reports Q2 2023 Revenues, Signals Shift Beyond COVID-19 Products

Company

MSD’s Q2 2023 Earnings: Keytruda and Gardasil Drive Growth Amid COVID-19 Sales Decline

Show More